Overall, the discussions demonstrate a positive attitude toward the article's relevance, with users sharing educational resources like videos and summaries, and highlighting new therapeutic approaches. For example, references to Garadicimab and clinical reviews show an active effort to connect research findings with practical applications, with a tone that balances curiosity and appreciation for advancements in understanding hereditary angioedema.
AgreementModerate agreement
Most posts recognize the importance of the publication, with some explicitly affirming its value in understanding hereditary angioedema.
InterestModerate interest
Discussions show moderate interest, with posts referencing new treatments like Garadicimab and emphasizing the need to understand the condition.
EngagementModerate engagement
Posts include shares of related videos and summaries, indicating a genuine effort to engage deeply with the content.
ImpactModerate impact
The discussions suggest that the publication has potential influence on both clinical understanding and treatment, demonstrated by mentions of pharmacology and clinical implications.
Abstract in brief
Hereditary angioedema (HAE) is a genetic disorder caused by mutations affecting the C1 esterase inhibitor, leading to episodes of swelling and sometimes abdominal pain, with types I, II, and III based on specific genetic mutations.
The condition typically presents in early adulthood with symptoms like nonpitting swelling, and triggers such as stress, infections, or trauma; laboratory tests show abnormal C1INH levels and elevated bradykinin.
Treatment options include immediate infusion of C1INH, receptor antagonists, and kallikrein inhibitors during attacks, as well as long-term preventive therapies like regular C1INH infusions to reduce the frequency and severity of symptoms.]
This newly published review aims to thoroughly understand hereditary #angioedema, its clinical presentation, and how to treat it: https://t.co/LTwmIYg1C1 https://t.co/bZmThg6GF5
Hereditary angioedema (HAE) is a genetic disorder characterized by swelling episodes and abdominal pain due to C1 esterase inhibitor mutations. Diagnosis involves clinical and laboratory assessments, with treatment…
This video explains how garadacimab, an FDA-approved monthly injection, prevents hereditary angioedema attacks by targeting Factor XIIa, offering a new treatment option for patients aged 12 and older.
Mar 26, 2023 · 13 likes · 4 shares · 62,123 followersView post →
AT
Advances in Therapy
@AdvancesTherapy · X
This newly published review aims to thoroughly understand hereditary #angioedema, its clinical presentation, and how to treat it: https://t.co/LTwmIYg1C1 https://t.co/bZmThg6GF5
10.1007/s12325- 022-02401-0. III. ĐIỀU HÒA HOẠT HÓA BỔ THỂ Yếu Tố Tăng Tốc Phân Hủy (DAF). Định Nghĩa. • Protein bề mặt tế bào liên kết với glycolipid. • Phá ...